Table 4 Change in CPRS.

From: Safety and efficacy of one-dose nocturnal levetiracetam for the treatment of self-limited epilepsy with centrotemporal spikes: a randomized clinical trial

Variables

Group

n

Baseline

After12m

SD

P

Conduct problem

A

65

0.39 ± 0.1

0.39 ± 0.11

0.08

0.448

B

62

0.36 ± 0.13

0.32 ± 0.11

0.09

0.006

C

65

0.38 ± 0.11

0.34 ± 0.1

0.09

< 0.001

F

  

1.385

10.155

  

P

  

0.253

< 0.001

  

Learning problem

A

65

0.62 ± 0.19

0.6 ± 0.16

0.18

0.308

B

62

0.57 ± 0.13

0.56 ± 0.17

0.14

0.329

C

65

0.56 ± 0.13

0.56 ± 0.16

0.17

0.43

F

  

2.497

59.614

  

P

  

0.085

< 0.001

  

Psychosomatic problem

A

65

0.24 ± 0.13

0.26 ± 0.17

0.17

0.15

B

62

0.2 ± 0.14

0.21 ± 0.15

0.16

0.317

C

65

0.2 ± 0.15

0.24 ± 0.16

0.16

0.026

F

  

2.047

90.461

  

P

  

0.132

< 0.001

  

Impulsivity-hyperactivity problem

A

65

0.39 ± 0.22

0.43 ± 0.21

0.18

0.022

B

62

0.34 ± 0.21

0.38 ± 0.22

0.2

0.081

C

65

0.33 ± 0.23

0.33 ± 0.19

0.22

0.41

F

  

1.23

16.989

  

P

  

0.295

< 0.001

  

Anxiety

A

65

0.07 ± 0.13

0.08 ± 0.12

0.15

0.343

B

62

0.12 ± 0.18

0.1 ± 0.14

0.2

0.214

C

65

0.13 ± 0.18

0.13 ± 0.17

0.21

0.44

F

  

2.716

52.112

  

P

  

0.069

< 0.001

  

Hyperactivity Index

A

65

0.49 ± 0.11

0.51 ± 0.13

0.11

0.052

B

62

0.48 ± 0.11

0.45 ± 0.13

0.11

0.024

C

65

0.41 ± 0.11

0.43 ± 0.11

0.1

0.062

F

  

8.701

129.84

  

P

  

< 0.001

< 0.001

  
Back to article page